Selank: where immune biology meets brain signaling Selank connects two worlds: immune biology and brain signaling. Its story asks whether redesigning a natural peptide can influence anxiety and the response to stress. Developed in Moscow through the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology, its research lineage includes Nikolay Myasoedov and Sergei Seredenin. A 1995 animal study described the molecule as TP-7, giving it more than thirty years of published research history. Selank contains seven amino acids. It starts with tuftsin, a four-amino-acid fragment of an immune protein. Adding three amino acids was intended to improve stability and extend its biological activity. Researchers have investigated brain signaling, including the GABA system, which helps regulate neuronal activity. In 2016, scientists reported changes in neurotransmission-related gene expression in rat brain tissue. This offers clues, rather than one fully established human mechanism. Human research includes a 2008 study of sixty-two people with generalized anxiety disorder or neurasthenia, a diagnosis involving fatigue and related symptoms. Thirty received Selank and thirty-two received medazepam. The authors reported similar anxiety-reducing effects, with additional improvements in fatigue-related symptoms in the Selank group. This small comparison used another medicine rather than placebo. Larger independent studies are needed to establish how these findings translate to broader populations. Selank differs from Semax: their parent molecules and research histories are distinct. It is not an FDA-approved anxiety treatment, and long-term safety remains incompletely characterized. Its appeal is a peptide approach to stress and emotional regulation: exploring how an immune-derived fragment can open a new question in neuroscience. World Peptide Foundation. Peptides in 2. Every experience matters.